Patients who all are receiving Iclusig in clinical trials will keep on therapy currently. Reductions in Iclusig dosage from 45 mg daily will be implemented on a trial-by-trial basis for sufferers whose Iclusig treatment can be ongoing. The dosage of Iclusig in patients who are currently signed up for the EPIC trial will be reduced to 30 mg daily unless they have attained a significant molecular response or reach one in the future, in which case the dosage will be further reduced to 15 mg daily.All individuals from whom cells samples were obtained supplied written educated consent. Clinical Specimens We obtained snap-frozen or paraffin-embedded specimens of tumors and surrounding nontumor hepatic cells from 455 sufferers with hepatocellular carcinoma who had undergone radical resection between 1999 and 2003 at the Liver Cancer Institute of Fudan University in Shanghai or at the University of Hong Kong Medical Centre in Hong Kong .4 Samples of normal liver cells were acquired from eight disease-free liver donors.22 Our analyses involved three different cohorts of sufferers. Cohort 1 contains 241 patients with hepatocellular carcinoma for whom microRNA microarray data were obtainable, as described previously.21 Data from these sufferers were analyzed to search for microRNAs that were associated with survival and sex.